ContraFect (CFRX) Earning Somewhat Favorable News Coverage, Report Shows
News articles about ContraFect (NASDAQ:CFRX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ContraFect earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.8888194052648 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of ContraFect (CFRX) remained flat at $$1.19 during mid-day trading on Friday. 42,570 shares of the company’s stock were exchanged, compared to its average volume of 170,358. ContraFect has a 1-year low of $0.80 and a 1-year high of $2.50. The stock has a market capitalization of $87.65, a price-to-earnings ratio of -5.17 and a beta of -0.85.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/contrafect-cfrx-earning-somewhat-favorable-news-coverage-report-shows/1807011.html.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.